TABLE 1.
The demographic, clinical and laboratory characteristics of SMA, ALS, and control
|
SMA (n = 10) |
ALS (n = 10) |
Control (n = 10) |
p Value | p’ Value | P” Value | |
|---|---|---|---|---|---|---|
| Age (years) | 26.80 ± 6.37 | 50.00 ± 11.32 | 46.40 ± 11.18 | <.00 1 | <.001 | .483 |
| Sex (male) | 8(80%) | 6 (60%) | 7 (70%) | .329 | .606 | .639 |
| Disease duration (months) | 275.0 (138.0, 343.3) | 14.0 (7.0, 29.0) | <.001 | |||
| ALSFRS‐R | 32.60 ± 10.28 | 38.40 ± 5.97 | .144 | |||
| DPR | 0.06 (0.03, 0.09) | 0.47 (0.16, 1.93) | <.001 | |||
| Laboratory parameters | ||||||
| Serum CK (U/L) | 91.0 (55.3, 811.0) | 257.0 (110.3, 329.3) | .266 | |||
| Serum Cr (μmol/L) | 22.5 (11.0, 36.5) | 56.50 (45.75, 67.75) | .001 | |||
| Serum NFL (pg/mL) | 8.19 (4.03, 30.18) | 22.44 (12.50, 32.72) | 2.35 (0.23, 6.49) | .193 | .092 | .001 |
| Serum pNFH (ng/mL) | 0.01 (0.01, 0.09) | 0.01 (0.01, 0.07) | 0.01 (0.01, 0.01) | .803 | .059 | .031 |
| CSF WBC | 0.5 (0, 2.5) | 2.0 (0.8, 2.5) | .251 | |||
| CSF Pro (g/L) | 0.32 (0.24, 0.44) | 0.42 (0.38, 0.69) | .086 | |||
| CSF NFL (pg/mL) | 596.97 (395.26, 699.70) | 6582.05 (2657.83, 10000.00) | <.001 | |||
| CSF pNFH (ng/mL) | 0.20 (0.18, 0.24) | 2.07 (0.46, 3.75) | .009 |
Note: Continuous data are given as mean ± SD or median (IQR) as appropriate. p represent the value of comparison between ALS and SMA; p’ represent the value of comparison between SMA and normal control; “p” represent the value of comparison between ALS and normal control.P‐value<0.0 is shown in bold.
ALSFRS‐R, revised ALS functional rating scale; DPR, disease progression rate; CK, creatine kinase; Cr, creatinine; CSF, cerebrospinal fluid; NFL, neurofilament light chain; pNFH, phosphorylated neurofilament heavy chain.